系统性应用抗CD20单克隆抗体美罗华治疗原发性皮肤B细胞淋巴瘤8疗程的疗效观察
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-An applicational observation作者机构：Department of Dermatology Venerology and Allergy Medical Faculty (Charité) Humboldt-University Berlin Schumannstr. 20/21 10117 Berlin Germany
出 版 物：《世界核心医学期刊文摘（皮肤病学分册）》 (Digest of the World Core Medical JOurnals:Dermatology)
年 卷 期：2005年第1卷第10期
页 面：34-35页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：美罗华 B细胞淋巴瘤8 CD20 单克隆抗体 淋巴瘤 霍奇金 嵌合抗体 滤泡型 中心型 膜抗原
摘 要：Background:Primary cutaneous B-cell lymphomas (PCBCLs)are characterized by restriction to the skin and a variable but mostly favourable prognosis. Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin,s B-cell lymphomas. Different studies have shown that the effectiveness and safety in the treatment of patients with low-grade follicular lymphoma is comparable to or even higher than the standard CHOP chemotherapy. So far it has been unclear whether an extended duration of therapy lead s to a benefit for the patients with PCBCL. Objectives:To evaluate the objective response rate, time to progression, remission quality and histological changes and to compare our data with the literature. Patients/Methods:Ten patients with PCBCL [eight with follicle centre cell lymphoma (FCCL), one with marginal zone lymphoma (MZL) and one with diffuse large B-cell lymphoma of the leg (DLBCL)]were treated by intravenous application of a chimeric antibody against the CD20 transmembrane antigen (rituximab) with a dosage of eight cycles, 375 mg m-2 body surface, weekly. Results:The treatment regimen resulted in clinical overall response in 9 of 10 patients, in particular there were seven complete responses (70%) plus two partial responses (20%). The median duration of remission (durable remission, DR) is 23 months (4-30 months) to date. Histological assessment of responses in four patients showed no tumour-specific infiltration. In two patients histology revealed a residual infiltration and in one patient an increasing infiltration. In two patients no histology was taken after treatment; one patient developed a new lesion. No severe side-effects occurred. Observed side-effects were two bacterial infections, two patients with shivering during infusion, one patient with sweating for months and one patient with persisting itching. As expected the B-cell count in peripheral blood was depressed in all patients after infusion. Conc
维普期刊数据库
同方期刊数据库